It’s preposterous for Morgan Stanley to model zero loss of market share by Botox out to 2030. Moreover, the excerpt you posted makes no mention of Daxxify’s sales in therapeutic indications, which will surely be contributing well before 2030.
Daxxify’s fewer visits issue is a red herring, IMO. Injectors are seeking more profit per patient visit, not more visits per se.
Thanks for sharing the report details. My take is for such cosmetic Tx, patients drive the business model insofar as more they are satisfied & happy, more referrals and obvsly more patients move to Daxxify. So any purported loss of fewer visits will be more than compensated by satisfied patients volume.
Market Data 
Markets 
AI
